Efficacy & Safety of DaxibotulinumtoxinA (DAXI) for Injection for

See also
Status	Clinical Trial	Phase
Completed	`NCT01808742` - Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device	N/A
Completed	`NCT01801826` - A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device	N/A
Completed	`NCT01797094` - BOTOX® in the Treatment of Upper Facial Lines in Japan	Phase 3
Completed	`NCT04763265` - Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT01808742 - Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

N/A

Completed

NCT01801826 - A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

N/A

Completed

NCT01797094 - BOTOX® in the Treatment of Upper Facial Lines in Japan

Phase 3

Completed

NCT04763265 - Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03786770
Study type	Interventional
Source	Revance Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	January 24, 2019
Completion date	March 9, 2020

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms